These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8092156)

  • 21. Parameters that influence the outcome of nausea and emesis in cisplatin based chemotherapy.
    Tsavaris N; Kosmas C; Mylonakis N; Bacoyiannis C; Kalergis G; Vadiaka M; Boulamatsis D; Iakovidis V; Kosmidis P
    Anticancer Res; 2000; 20(6C):4777-83. PubMed ID: 11205218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy.
    Sledge GW; Einhorn L; Nagy C; House K
    Cancer; 1992 Nov; 70(10):2524-8. PubMed ID: 1423181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of ondansetron plus dexamethasone in fractionated chemotherapy.
    Räth U; Upadhyaya BK; Arechavala E; Böckmann H; Dearnaley D; Droz JP; Fosså SD; Henriksson R; Aulitzky WE; Jones WG
    Oncology; 1993; 50(3):168-72. PubMed ID: 8459987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting.
    Buxton MJ; O'Brien BJ
    Br J Cancer Suppl; 1992 Dec; 19():S64-7. PubMed ID: 1467204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The real costs of emesis--an economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy for cancer.
    Cunningham D; Gore M; Davidson N; Miocevich M; Manchanda M; Wells N
    Eur J Cancer; 1993; 29A(3):303-6. PubMed ID: 8398322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
    Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of postoperative nausea and vomiting with ondansetron in patients administered anti-neoplastic agents].
    Morimoto Y; Nakamura M; Tamura T; Kunii T; Shimizu K; Miyauchi Y
    Masui; 1996 Sep; 45(9):1096-9. PubMed ID: 8905945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of ondansetron and granisetron on chemotherapy-induced emesis in adults: the need for comparative pharmacoeconomic data.
    Hedayati S; Moatti JP; Seitz JF
    Clin Ther; 1994; 16(3):569-80. PubMed ID: 7923321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer.
    Lachaine J; Laurier C; Langleben A; Vaillant L
    Crit Rev Oncol Hematol; 1999 Nov; 32(2):105-12. PubMed ID: 10612010
    [No Abstract]   [Full Text] [Related]  

  • 30. Re-examination of clinical aspects of pharmacoeconomic analysis.
    Rubenstein EB; Elting LS
    Am J Hosp Pharm; 1994 Dec; 51(23):2970-3. PubMed ID: 7879813
    [No Abstract]   [Full Text] [Related]  

  • 31. [Experimental study on the control of cisplatin-induced emesis in dogs].
    Ito J; Okada M; Abo T; Okamoto Y; Yamashita T; Takahashi K
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):706-10. PubMed ID: 3827261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative trials of ondansetron versus metoclopramide in the prevention of acute cisplatin-induced emesis.
    Hesketh PJ
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):33-40. PubMed ID: 1387248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Global experience with ondansetron and future potential.
    Butcher ME
    Oncology; 1993; 50(3):191-7. PubMed ID: 8459991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low dose ondansetron and dexamethasone: a cost effective alternative to high dose metoclopramide/dexamethasone/lorazepam in the prevention of acute cisplatin induced emesis.
    Sands R; Roberts JT; Marsh M; Gill A
    Clin Oncol (R Coll Radiol); 1992 Jan; 4(1):67. PubMed ID: 1531293
    [No Abstract]   [Full Text] [Related]  

  • 35. Ondansetron versus metoclopramide in the prevention of chemotherapy-induced nausea and vomiting - a metaanalysis.
    Rusthoven J; Obrien B; Rocchi A
    Int J Oncol; 1992 Sep; 1(4):443-50. PubMed ID: 21584565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy.
    Goldspiel BR; Kohler DR
    Obstet Gynecol; 1994 Sep; 84(3):483-4. PubMed ID: 8058256
    [No Abstract]   [Full Text] [Related]  

  • 37. Ondansetron: a cost-effective advance in anti-emetic therapy.
    Cox F; Hirsch J
    Oncology; 1993; 50(3):186-90. PubMed ID: 8459990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ondansetron in chemotherapy-induced emesis. Our experience.
    Framarino dei Malatesta M; Veneziano M; Fiorelli C; Bandiera AF; Yacoub M; Toccaceli Blasi MR; Marzetti L
    Eur J Gynaecol Oncol; 1995; 16(2):97-106. PubMed ID: 7641745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Parkinsonism following i.v. administration of high-dose metoclopramide used as an antiemetic agent during cancer chemotherapy.
    Markman M; Newman DR; Hawkins RS
    Cancer Treat Rep; 1985 Mar; 69(3):341-2. PubMed ID: 4038919
    [No Abstract]   [Full Text] [Related]  

  • 40. High-dose metoclopramide + lorazepam versus low-dose metoclopramide + lorazepam + dehydrobenzperidol in the treatment of cisplatin-induced nausea and vomiting.
    Herrstedt J; Hannibal J; Hallas J; Andersen E; Laursen LC; Hansen M
    Ann Oncol; 1991 Mar; 2(3):223-7. PubMed ID: 2043493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.